ApcinteX develops an anticoagulant therapy targeting the activated protein C (APC) pathway to treat hemophilia. This approach aims to enhance blood coagulation control in patients, reducing the risk of bleeding episodes associated with the condition.
Funding
Funding not disclosed
Founders
Product
Problem
Hemophilia patients face the risk of bleeding episodes due to impaired blood coagulation. Current treatments may not fully address the need for enhanced blood coagulation control.
Solution
ApcinteX is developing an anticoagulant therapy that targets the activated protein C (APC) pathway. By modulating the APC pathway, the therapy aims to improve blood coagulation control in hemophilia patients. This approach seeks to reduce the frequency and severity of bleeding episodes, leading to improved patient outcomes. The therapy is designed to provide a more balanced and effective approach to managing hemophilia.
Target Audience
The primary target audience is hemophilia patients and healthcare providers specializing in hematology and blood disorders.
Features
- Targets the activated protein C (APC) pathway
- Designed to enhance blood coagulation control
- Aims to reduce the risk of bleeding episodes in hemophilia patients